Arbutus Biopharma Corporation (NASDAQ:ABUS) Q4 2022 Earnings Call Transcript

William Collier: Yes. So I mean, as I said in my prepared remarks, I mean, I think the key thing that we would want to see is a further reduction in s-antigen. So you treat with 729. And then potentially after you add in these other agents, a further reduction in s-antigen, which could be reflective of immune response. But I will add the caveat that we’ve seen in other studies that, that doesn’t necessarily happen immediately with interferon. And sometimes it takes a while. Sometimes it’s after the interferon therapy is stopped. So we’ll have to see how our data pans out, and we’ll make the appropriate commentary when we do that update.

Roy Buchanan: Okay, great. Thank you.

Operator: Ladies and gentlemen, this does conclude the Q&A portion of today’s call. I’d like to turn the call back over to Bill for any closing remarks.

William Collier: Well, thank you very much for joining us this morning. I’m also thankful my voice managed to hold up. We do appreciate your continued interest in Arbutus, and we especially look forward to providing you with further updates as we progress the development of our HBV and coronavirus assets. So thanks again for joining. And operator, that concludes our call.

Operator: Ladies and gentlemen, this does conclude today’s presentation. You may now disconnect, and have a wonderful day.